Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/57310
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_MultimethodAnalysisAdherence.pdf1,91 MBAdobe PDFVisualizar/Abrir
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAlves, Bárbara Manuella Cardoso Sodré-
dc.contributor.authorAraújo, Wildo Navegantes de-
dc.contributor.authorZimmermann, Ivan Ricardo-
dc.contributor.authorMetzger, Ingrid Ferreira-
dc.contributor.authorVerdam, Maria Christina dos Santos-
dc.contributor.authorCola, João Paulo-
dc.contributor.authorPrado, Thiago Nascimento do-
dc.contributor.authorPereira, Leonardo Régis Leira-
dc.contributor.authorOliveira Filho, Alfredo Dias de-
dc.contributor.authorMaciel, Ethel Leonor Noia-
dc.contributor.authorTavares, Noemia Urruth Leão-
dc.date.accessioned2026-10-22T15:00:56Z-
dc.date.available2026-10-22T15:00:56Z-
dc.date.issued2026-03-19-
dc.identifier.citationALVES, Bárbara Manuella Cardoso Sodré et al. Multimethod analysis of adherence to preventive treatment for tuberculosis: a pragmatic randomized clinical trial. BMC Infections Diseases, v. 26, art. n. 975, 2026. DOI: https://doi.org/10.1186/s12879-026-13069-0. Disponível em: https://link.springer.com/article/10.1186/s12879-026-13069-0. Acesso em: 22 out. 2026.pt_BR
dc.identifier.urihttp://repositorio.unb.br/handle/10482/57310-
dc.language.isoengpt_BR
dc.publisherSpringerpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleMultimethod analysis of adherence to preventive treatment for tuberculosis : a pragmatic randomized clinical trialpt_BR
dc.typeArtigopt_BR
dc.subject.keywordTuberculose - tratamento preventivopt_BR
dc.subject.keywordPersistência terapêuticapt_BR
dc.subject.keywordIsoniazidapt_BR
dc.subject.keywordTuberculose latentept_BR
dc.rights.licenseOpen Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.pt_BR
dc.identifier.doihttps://doi.org/10.1186/s12879-026-13069-0pt_BR
dc.description.abstract1Tuberculosis Preventive Treatment (TPT) can reduce the likelihood of active disease from 1.6% to 0.6% in contacts of infectious cases. In Brazil, four therapeutic regimens for Tuberculosis infection (TBI) are currently in use, with isoniazid (INH) being the predominant regimen. The perspective of study this study is that simplifying the regimen by reducing the number of tablets required per dose could lead to improved adherence to TPT. Therefore, in 2018, the INH 300 mg dosage (one tablet per day) was introduced to improve adherence, since previously, only the 100 mg presentation was available. The present study is a pragmatic randomized clinical trial to assess adherence to treatment with 300 mg INH versus 100 mg INH, which included volunteers aged over 18 years from February 2021 to July 2022. Adherence was measured in three ways: self-reported, treatment persistence and the medication possession ratio (MPR). The results demonstrated that the INH 300 mg group had lower dropout rates and higher adherence to treatment rates, although the difference was not statistically significant. The 300 mg INH group presented greater persistence, indicating a lower probability of abandonment. This study compared two presentations of INH for TPT: a control group, in which three 100 mg tablets were administered, and an intervention group, in which one 300 mg tablet was administered, and revealed several important trends. However, not all of them reached statistical significance. These findings may support the incorporation of new therapeutic strategies in the management of TBI, as well as improve regular follow-up by health professionals for people on TPT, with the aim of optimizing the results of control and elimination programs.pt_BR
dc.identifier.orcidhttps://orcid.org/ 0000-0001-9875-4334pt_BR
dc.contributor.affiliationUniversidade de Brasília, Laboratory of Evidence and Pharmaceutical Studiespt_BR
dc.contributor.affiliationUniversidade de Brasília, Postgraduate Program in Pharmaceutical Sciencespt_BR
dc.contributor.affiliationUniversity of Brasília, Postgraduate Program in Collective Healthpt_BR
dc.contributor.affiliationUniversity of Brasília, School of Medicine, Postgraduate Program in Tropical Medicinept_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade UnB Ceilândiapt_BR
dc.contributor.affiliationNational Institute for Science and Technology for Health Technology Assessmentpt_BR
dc.contributor.affiliationUniversidade de Brasília, Laboratory of Evidence and Pharmaceutical Studiespt_BR
dc.contributor.affiliationUniversity of Brasília, Postgraduate Program in Collective Healthpt_BR
dc.contributor.affiliationUniversity of Brasília, School of Medicine, Postgraduate Program in Tropical Medicinept_BR
dc.contributor.affiliationUniversidade de Brasília, Laboratory of Evidence and Pharmaceutical Studiespt_BR
dc.contributor.affiliationUniversidade Federal do Espírito Santo, Laboratory of Epidemiology, Postgraduate Program in Collective Healthpt_BR
dc.contributor.affiliationUniversidade Federal do Espírito Santo, Laboratory of Epidemiology, Postgraduate Program in Collective Healthpt_BR
dc.contributor.affiliationUniversity of São Paulo, Ribeirão Preto School of Pharmaceutical Sciencespt_BR
dc.contributor.affiliationFederal University of Sergipept_BR
dc.contributor.affiliationUniversidade Federal do Espírito Santo, Laboratory of Epidemiology, Postgraduate Program in Collective Healthpt_BR
dc.contributor.affiliationUniversidade de Brasília, Laboratory of Evidence and Pharmaceutical Studiespt_BR
dc.contributor.affiliationUniversity of Brasília, Postgraduate Program in Pharmaceutical Sciencespt_BR
dc.description.unidadeFaculdade de Ciências da Saúde (FS)pt_BR
dc.description.unidadeDepartamento de Farmácia (FS FAR)pt_BR
dc.description.ppgPrograma de Pós-Graduação em Ciências Farmacêuticaspt_BR
dc.description.ppgPrograma de Pós-Graduação em Saúde Coletivapt_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.